The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.

《國(guó)際臨床腫瘤學(xué)雜志》（IJCO）歡迎關(guān)于臨床腫瘤學(xué)各個(gè)方面的原始研究論文，這些論文報(bào)告了新的和及時(shí)的研究結(jié)果。鼓勵(lì)進(jìn)行臨床試驗(yàn)報(bào)告。如果實(shí)驗(yàn)研究與臨床腫瘤學(xué)有明顯的相關(guān)性，也將被接受。日本臨床腫瘤學(xué)學(xué)會(huì)的會(huì)員資格不是提交該雜志的先決條件。收到論文的前提是：其內(nèi)容未全部或部分在其他地方出版；至少有兩名裁判員和編輯對(duì)其進(jìn)行同行評(píng)審，并對(duì)其語(yǔ)言和內(nèi)容進(jìn)行編輯性修改；編輯對(duì)其接受、拒絕和出版順序負(fù)責(zé)。